Beam Therapeutics Inc. Common Stock (BEAM) — Analysis Summary
Beam Therapeutics Inc. Common Stock (BEAM) has a market cap of $3.03B with year-over-year revenue growth of +120.0%. Net margin stands at -57.2%. The stock trades at a P/E ratio of -35.5.
Key Takeaways
- Revenue changed +120.0% year-over-year
- Net margin of -57.2%
- P/E ratio of -35.5
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, BEAM posted revenue growth of +120.0% and trades at a P/E of -35.5.
Beam Therapeutics Inc. Common Stock (BEAM)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -242.3% — severe operating losses
Net margin at -54.7% — significant losses
The latest filing shows negative free cash flow.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
540
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.90
Dividend Yield
3.06%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.